Company Analysis
Sign in

Passage Bio, Inc. (PASG)

Nasdaq: PASG · Biological Products, (No Diagnostic Substances) · Philadelphia, PA · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.1
◀ Past 5.4● Present 4.0▶ Future 6.0
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$45.5M+29.7%
Earnings per share$-14.35+31.8%
Operating cash flow-$31.5M+34.3%
Cash$46.3M+23.2%
Debtn/a
Shareholders’ equity$18.8M-69.4%
Shares, diluted3,172,870+3.1%
Return on equity-242.7%
The recordfrom its filings
Filings in 202644
Newest filingNov 10 · 10-Q
Annual reportMar 3, 2026
Quarterly reportNov 10, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$100,000
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$33.1MCash from operations -$32.6Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 6, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 9, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Oct 9, 2026 · SEC EDGAR · Form 424B3
Shelf offering
Open the filing on sec.gov
Sep 3, 2026 · SEC EDGAR · Form 425
Merger communication
Open the filing on sec.gov
Sep 3, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton PASG · research, not advice